| Company Name: |
EMMX Biotechnology LLC
|
| Tel: |
888-539-0666 |
| Email: |
info@emmx.com |
| Products Intro: |
Product Name:BMS 195614
CAS:253310-42-8
Purity:98% HPLC Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
BMS 195614 manufacturers
- BMS 195614
-
- $181.00 / 1mg
-
2024-11-19
- CAS:253310-42-8
- Min. Order:
- Purity: 97.7%
- Supply Ability: 10g
|
| | BMS 195614 Basic information |
| Product Name: | BMS 195614 | | Synonyms: | BMS 195614;4-[[[5,6-Dihydro-5,5-dimethyl-8-(3-quinolinyl)-2-naphthalenyl]carbonyl]amino]benzoic acid;BMS-195614 4-[[[5,6-Dihydro-5,5-dimethyl-8-(3-quinolinyl)-2-naphthalenyl]carbonyl]amino]benzoic acid | | CAS: | 253310-42-8 | | MF: | C29H24N2O3 | | MW: | 448.51246 | | EINECS: | | | Product Categories: | | | Mol File: | 253310-42-8.mol |  |
| | BMS 195614 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | <11.21mg/ml in DMSO |
| | BMS 195614 Usage And Synthesis |
| Uses | BMS 195614, is a selective neutral RARα inhibitor and exhibits no significant effect on NCoR binding. It decreases agonist-induced coactivator recruitment and SMRT binding to RAR. RARs, or Retinoic Acid Receptors, are nuclear hormone receptors that form heterodimers with RXRs (Retinoid X Receptors). | | Definition | ChEBI: BMS 195614 is a carboxamide resulting from the formal condensation of the carboxy group of 5,5-dimethyl-8-(quinolin-3-yl)-5,6-dihydronaphthalene-2-carboxylic acid with the amino group of p-aminobenzoic acid. It is a neutral retinoic acid receptor (RAR) alpha-selective antagonist (Ki = 2.5 nM). It displays no significant effect on nuclear receptor corepressor (NCoR) binding; moderately decreases SMRT binding to RAR. It antagonizes agonist-induced coactivator (CoA) recruitment. It has a role as a retinoic acid receptor alpha antagonist. It is a member of quinolines, a member of benzoic acids and a secondary carboxamide. |
| | BMS 195614 Preparation Products And Raw materials |
|